Entero Therapeutics Inc (ENTO)

$2.08

+0.01

(+0.48%)

Market is closed - opens 7 PM, 18 Jun 2024

Performance

  • $1.90
    $2.18
    $2.08
    downward going graph

    8.65%

    Downside

    Day's Volatility :12.84%

    Upside

    4.58%

    downward going graph
  • $1.87
    $37.40
    $2.08
    downward going graph

    10.1%

    Downside

    52 Weeks Volatility :95.0%

    Upside

    94.44%

    downward going graph

Returns

PeriodEntero Therapeutics IncIndex (Russel 2000)
3 Months
-30.2%
0.0%
6 Months
-30.2%
0.0%
1 Year
-30.2%
0.0%
3 Years
-30.2%
-20.9%

Highlights

Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
0.0%
Return On Equity TTM
0.0%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
0.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0

Analyst Recommendation

Technicals Summary

Sell

Neutral

Buy

Entero Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Entero Therapeutics Inc
Entero Therapeutics Inc
-27.02%
-30.2%
-30.2%
-30.2%
-30.2%
Moderna, Inc.
Moderna, Inc.
-2.21%
61.44%
11.0%
-30.77%
776.11%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.88%
22.86%
33.81%
94.34%
240.92%
Novo Nordisk A/s
Novo Nordisk A/s
5.61%
41.82%
73.65%
241.2%
437.92%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
6.24%
17.06%
38.23%
152.16%
166.21%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Entero Therapeutics Inc
Entero Therapeutics Inc
NA
NA
NA
0.0
0.0
0.0
NA
NA
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.72
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.58
30.58
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.48
49.48
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.16
31.16
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Entero Therapeutics Inc
Entero Therapeutics Inc
NA
$5.1M
-30.2%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$53.7B
776.11%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.2B
240.92%
30.58
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$636.1B
437.92%
49.48
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.1B
166.21%
31.16
39.46%

Company Information

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.

Organization
Entero Therapeutics Inc
Employees
9
CEO
James Sapirstein
Industry
Miscellaneous

FAQs